Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: A 7- year biochemical (PSA) progression analysis

Urology

Volumn 51, Issue 6, 1998, Pages 884-890

  Polascik, Thomas J ^a   Pound, Charles R ^a   DeWeese, Theodore L ^a   Walsh, Patrick C ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125;

AGED; ARTICLE; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM;

ADULT; AGED; BRACHYTHERAPY; DISEASE PROGRESSION; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 0032101041     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00153-8     Document Type: Article

References (18)

1. D'Amico A.V., Coleman C.N. Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer the jury is still out . J Clin Oncol. 14:1996;304-315.
2. 125iodine implantation of the prostate for clinically localized prostatic cancer. J Urol. 158:1997;23-29.
3. Ragde H., Blasko J.C., Grimm P.D., et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer. 80:1997;442-453.
4. Grimm P.D., Blasko J.C., Ragde H., et al. Does brachytherapy have a role in the treatment of prostate cancer? Hem Oncol Clin North Am. 10:1996;653-673.
5. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal iodine-125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 14:1996;449-453.
6. 125I prostate implantation. Int J Radiat Oncol Biol Phys. 37:1997;559-563.
7. Pound C.R., Partin A.W., Epstein J.I., et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy patterns of recurrence and cancer control . Urol Clin North Am. 24:1997;395-406.
8. Catalona W.J., Smith D.S. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 152:(5 Pt 2):1994;1837-1842.
9. Partin A.W., Pound C.R., Clemons J.Q., et al. Serum PSA after anatomic radical prostatectomy the Johns Hopkins experience after 10 years . Urol Clin North Am. 20:1993;713-725.
10. Epstein J.I., Pizov G., Walsh P.C. Correlation of pathological findings with progression following radical retropubic prostatectomy. Cancer. 71:1993;3582-3593.
11. Epstein J.I., Partin A.W., Sauvageot J., et al. Prediction of progression following radical prostatectomy a multivariate analysis of 721 men with long-term follow-up . Am J Surg Pathol. 20:1996;286-292.
12. Consensus statement guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
13. Critz F.A., Levinson A.K., Williams W.H., et al. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology. 49:1997;322-326.
14. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Conformal external beam treatment of prostate cancer. Urology. 50:1997;87-92.
15. Zietman A.L., Tibbs M.K., Dallow K.C., et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol. 40:1996;159-162.
16. Bastacky S.I., Wojno K.J., Walsh P.C., et al. Pathological features of hereditary prostate cancer. J Urol. 153:1995;987-992.
17. Cadeddu J.A., Partin A.W., Epstein J.I., et al. Stage D1 (T1-3, N1-3, M0) prostate cancer a case-controlled comparison of conservative treatment versus radical prostatectomy . Urology. 50:1997;251-255.
18. Epstein J.I. Incidence and significance of positive margins in radical prostatectomy specimens. Urol Clin North Am. 23:1996;651-663.